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Smad3 Signal Transducer Regulates Skin
Inflammation and Specific IgE Response in Murine
Model of Atopic Dermatitis
Minna Anthoni1, Guoying Wang1,2, Chuxia Deng3, Henrik J. Wolff4,5,6, Antti I. Lauerma7
and Harri T. Alenius1
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by itchy, dry, and inflamed
skin. Transforming growth factor (TGF)-b is an important fibrogenic and immunomodulatory factor that
regulates cellular processes in the injured and inflamed skin. This study examines the role of the TGF-b–Smad
signaling pathway using Smad3-deficient mice in a murine model of AD. Dermatitis was induced in mice by
epicutaneous application of ovalbumin (OVA) applied in a patch to tape-stripped skin. OVA-specific IgE and
IgG2a antibody levels were measured by ELISA. Skin biopsies from sensitized skin areas were used for RNA
isolation, histology, and immunohistochemical examination. The thickness of dermis was significantly reduced
in OVA-sensitized skin of Smad3/ mice. The defect in the dermal thickness was accompanied by a decrease in
the expression of mRNA for proinflammatory cytokines IL-6 and IL-1b in the OVA-sensitized skin. In contrast,
the number of mast cells was significantly increased in OVA-sensitized skin of Smad3/ mice, which also
exhibited elevated levels of OVA-specific IgE. These results demonstrate that the Smad3-pathway regulates
allergen-induced skin inflammation and systemic IgE antibody production in a murine model AD. The Smad3
signaling pathway might be a potential target in the therapy of allergic skin diseases.
Journal of Investigative Dermatology (2007) 127, 1923–1929; doi:10.1038/sj.jid.5700809; published online 12 April 2007
INTRODUCTION
Atopic dermatitis (AD) is a common chronic inflammatory
skin disease characterized by dry inflamed skin, which is
always itchy (Hanifin and Rajka, 1980). AD usually starts in
early childhood and its prevalence has been increasing in
recent years in parallel with other atopic conditions, such as
asthma, rhinitis, and allergies. Both genetic and environ-
mental factors play an important role in developing AD
(Spergel and Paller, 2003; Foroughi et al., 2005; Linneberg
et al., 2006). Approximately, 80% of patients with AD have
elevated levels of serum IgE and specific IgE antibodies to
environmental allergens suggesting an important role of
allergens in AD. In the acute phase of AD, skin lesions show
a marked infiltration with activated CD4þ T cells within the
dermis, and Th2-type cytokines characterize the inflam-
matory response. In the chronic phase of the disease,
however, Th1-type cytokines are highly expressed and
predominate over Th2 cytokines. The molecular and cellular
mechanisms underlying AD are unfortunately not well
understood, which hampers the development of specific
treatments for the disease.
It has been reported recently that children with AD exhibit
a significantly higher proportion of a low transforming growth
factor (TGF)-b1 cytokine-producing allele compared with
healthy controls (Arkwright et al., 2001). TGF-b is an
important fibrogenic and immunomodulatory factor that
regulates cellular processes in injured and inflamed skin.
TGF-b family proteins have multiple functions, which in
some cases can be contradictory, either stimulating or
inhibiting immune cell functions (Smeltz et al., 2005; Ito
et al., 2006; Meadows et al., 2006). TGF-b regulates
numerous cellular responses, such as differentiation, prolif-
eration, migration, and apoptosis. TGF-b is produced by most
cell types, such as immune and structural cells in different
tissues (Chu et al., 2000; Harrison et al., 2006; Meadows
et al., 2006). TGF-b proteins are able to elicit different effects
at different concentrations (Chen and Khalil, 2006; Funaba
et al., 2006). Thus, TGF-b is secreted by many sources and
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different mediators such as pro- and antiinflammatory
compounds can modulate its synthesis.
Mature TGF-b binds TGF-b receptor types I and II to
initiate signaling. TGF-b signal transducers called Smads are
intracellular proteins, transcription factors of B500 amino
acids in length, with two globular domains, an N-terminal
mad homology 1 domain and a C-terminal mad homology 2
domain (Shi and Massague´, 2003; Massague´ et al., 2005).
There are three families of Smads: receptor-activated
(R-) Smads (Smads 1, 2, 3, 5, and 8), common-partner
(Co-) Smads (Smad 4), and the inhibitory (I-) Smads (Smads
6 and 7). Smads 2 and 3 are activated by TGF-b and
activin receptors, whereas Smads 1, 5, and 8 are activated
by bone morphogenetic protein (Piek et al., 1999). Smads
deliver TGF-b signals from the cytoplasm to the nucleus
controlling the expression of target genes in a cell
type-specific manner. Increased activation of the TGF-b
pathway has been observed in the skin and lung, especially
during tissue injury and inflammation (Munger et al.,
1999).
In this study, we examined the role of TGF-b–Smad
signaling in AD using Smad3-deficient mice and a murine
model of AD. We demonstrate here that Smad3-deficiency
modulates allergen-induced skin inflammation and specific
IgE responses after epicutaneous (EC) ovalbumin (OVA)
sensitization.
RESULTS
Dermal thickness is reduced in OVA-sensitized skin sites
of Smad3/ mice
The thickness of dermis and epidermis was significantly
increased in OVA-sensitized skin sites of wild-type (WT) mice
compared with saline-treated controls (Figure 1). Similarly,
the thickness of the epidermis was enhanced in the OVA-
sensitized skin of Smad3/ mice compared with their saline-
treated controls although the difference was not statistically
significant (Figure 1g). No significant difference in the
epidermal thickness was found in Smad3/ mice compared
with WT mice after OVA sensitization (Figure 1g). In contrast,
however, dermal thickening was significantly reduced after
EC OVA sensitization in Smad3/ mice compared with their
WT littermates (Figure 1h). A representative picture of the
skin morphology after EC sensitization with OVA and saline
is provided in Figure 1a–e.
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Figure 1. Histological changes in the (g) epidermis and (h) dermis of mice skin after EC exposure to OVA or saline. The results are shown as mean7SEM.
**Po0.01, ***Po0.001, ns: not statistically significant. (a and d) Hematoxylin and eosin-stained skin sections are from saline groups and (b and e) OVA
groups; Masson-trichrome-stained skin sections are from OVA-treated WT and Smad3/mice; (d–f) Smad3/ mice and (a–c) WT mice; bar¼ 100mm;
n¼ 8–14 mice per group.
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Collagen fiber staining revealed a clear-cut increase in the
collagen fiber deposition in OVA-sensitized skin of WT mice
compared with saline controls. In contrast, no difference in
the collagen deposition was observed in the OVA-sensitized
skin of Smad3/ mice compared with their saline-treated
controls. Moreover, collagen deposition was significantly
reduced in the skin of Smad3-deficient mice compared
with WT mice after EC OVA sensitization. A representative
picture of the collagen fiber deposition after EC sensitization
with OVA in WT and Smad3/ mice is provided in Figure 1c
and f.
Smad3/ mice exhibit increased numbers of mast cells in the
OVA-sensitized skin
The number of mast cells was significantly increased in the
OVA-sensitized skin of Smad3/ mice compared with the
saline group (Figure 2). Interestingly, mast cell numbers
remained at a low level in OVA-sensitized WT mice and the
difference in mast cell numbers between OVA-sensitized skin
of WT mice and Smad3/ mice was statistically significant
(Figure 2).
The number of skin-infiltrating eosinophils was signifi-
cantly increased in OVA-sensitized WT mice compared with
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Figure 2. Mast cells were significantly increased in OVA-sensitized Smad3/ mice, but remained at a low level in OVA-sensitized WT mice. The number
of eosinophils, CD11c-, CD3-, CD4-, and CD8-positive cells was significantly increased in mice skin after repeated EC exposures to OVA. The cells were
counted under a light microscope and the results are expressed as cells per high-power field (original magnification 40, eosinophils original magnification
100). (a and d) Mast cells, (b and e) CD4þ , (c and f) CD8þ . (d–f) OVA-treated Smad3/ mice and (a–c) OVA-treated WT mice; bar¼ 100mm. The data
are shown as mean7SEM. *Po0.05, **Po0.01, ***Po0.001, ns: not statistically significant; n¼ 6–14 mice per group.
www.jidonline.org 1925
M Anthoni et al.
Smad3 Signal Transducer in Atopic Dermatitis
saline-sensitized controls (Figure 2). An increase in the
numbers of eosinophils after OVA sensitization was also
seen in Smad3/ mice compared with their saline-treated
controls, but the difference was not statistically significant.
Immunohistochemical staining demonstrated that the num-
bers of CD11þ cells were equally elevated in the skin of
Smad3/ mice and their WT littermates after OVA sensitiza-
tion (Figure 2). Moreover, increased numbers of CD3þ ,
CD4þ , and CD8þ cells were observed in the skin of
Smad3/ mice and WT mice after EC OVA sensitization.
However, there were no significant differences in lymphocyte
numbers between the Smad3/ mice and WT mice
(Figure 2). We also analyzed expression of forkhead box
P3 mRNA, a marker for regulatory T cells, in the sensitized
skin sites of WT and Smad3-deficient mice. No signifi-
cant differences between any of the study groups were
detected.
Expression of IL-6 and IL-1b mRNA is drastically reduced in the
OVA-sensitized skin of Smad3/ mice
mRNA expression of proinflammatory cytokines TNF-a, IL-6,
and IL-1b was significantly increased in OVA-sensitized skin
sites of WT mice compared with saline-treated controls
(Figure 3). Interestingly, expression of IL-6 and IL-1b mRNA
was dramatically decreased in OVA-sensitized skin of
Smad3/ mice compared with their WT littermates (Fig-
ure 3). There were no significant difference in the expression
of IL-6, IL-1b, and TNF-a mRNA between OVA- and saline-
sensitized skin in Smad3/ mice (Figure 3).
The expression levels of a major Th2 cytokine IL-4 and
Th1 cytokine IFN-g were significantly higher in the skin of
OVA-sensitized mice compared with saline-treated controls,
but no significant difference between Smad3/ and WT
mice was observed (Figure 3).
OVA-specific IgE levels are elevated in OVA-sensitized
Smad3/ mice
OVA-specific IgE levels were increased both in Smad3/
and WT mice sensitized with OVA (Figure 4). However,
OVA-specific IgE levels were significantly elevated in
Smad3/ mice compared with their WT littermates
(Figure 4). In addition, the levels of OVA-specific IgG2a
were induced after OVA sensitization in both mice groups,
but there were no significant differences in antibody levels
between WT and Smad3/ mice (Figure 4).
DISCUSSION
The role of TGF-b–Smad3 signaling in the immunoregulation
and pathophysiology of allergic skin disorders is unknown.
However, mice lacking Smad3 show accelerated wound
healing and an impaired local inflammatory response
(Ashcroft et al., 1999). Although the mechanisms of fibrosis
and wound healing may differ from the mechanisms involved
in inflammation, we anticipated, based on the wound repair
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Figure 3. mRNA expression of cytokines in mice skin after EC exposure to OVA or saline. Real-time quantitative RT-PCR was used to analyze the mRNA
expression levels. IL-6 and IL-1b mRNA levels were significantly increased in OVA-sensitized WT mice compared with OVA-sensitized Smad3/ mice.
The levels of IL-4, IFN-g, and TNF-a mRNA were significantly higher in OVA-sensitized mice compared with saline group, but no significant difference
between Smad3/ and WT mice was detected. Bars and errors represent mean7SEM. *Po0.05, **Po0.01, ***Po0.001. NS: Not statistically significant;
n¼ 6–16 mice per group.
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studies, that the defect in TGF-b–Smad3 signaling causes
milder skin injury and inflammatory response in the experi-
mental model of AD. Indeed, EC exposure to OVA resulted in
significantly reduced dermal thickening and drastically
decreased expression of IL-6 and IL-1b mRNA in the skin of
Smad3/ mice. Interestingly, however, the numbers of dermal
mast cells and OVA-specific IgE levels were significantly
increased in Smad3/ mice after OVA-sensitization.
The increased deposits of collagen may cause skin
thickening, which is a characteristic feature of human AD.
Extracellular matrix and the regulation of the synthesis of
matrix molecules are key elements in the pathology of many
skin diseases. The balance in the synthesis and breakdown of
connective tissue is tightly controlled by the release of
mediators, including TGF-b, from inflammatory cells or
connective tissue cells, which can influence collagen and
matrix metalloproteinase production in both paracrine and
autocrine fashions (Eckes et al., 2000). Disorders cause
wound-healing defects or the development of fibrosis.
Fibrosis is a normal consequence of chronic inflammation
and tissue injury with excessive cell accumulation, skin
thickening, and deposition of extracellular matrix proteins.
There are a number of studies showing the involvement of
Smad3–TGF-b signaling in the collagen transcription and in
the mechanisms of fibrosis (Chen et al., 1999; Verrecchia
et al., 2000). Smad3 transmits TGF-b signals from the
receptor to the procollagen gene in human fibroblasts (Chen
et al., 1999). It is, thus, possible that Smad3 regulates
collagen production in our model of AD. Decreased
secretion of collagen in Smad3/ mice may result in
reduced dermal thickness after EC OVA sensitization.
The proinflammatory cytokines TNF, IL-1, and IL-6 are
known to participate in the pathogenesis of AD by
orchestrating the interactions between resident and infiltrat-
ing cells. Interestingly, the expression of skin IL-6 and IL-1b
mRNA was drastically decreased in the OVA-sensitized skin
of Smad3/ mice compared with WT mice. Several studies
have demonstrated the interaction between IL-6 and TGF-b in
disease states. An intestinal epithelial cell line study
demonstrates a cross-talk between TGF-b and IL-6, and it is
suggested that TGF-b may play a role in the negative
regulation of IL-6 signaling in intestinal epithelial cells (Walia
et al., 2003). Moreover, a recent study showed that IL-6
increased TGF-b1-dependent Smad3 signaling in proximal
tubular cells. Zhang et al. (2005) suggested that synergistic
effect between IL-6 and TGF-b1 might lead to an enhanced
profibrotic response in the kidney. Furthermore, it has been
recently reported that IL-1b-induced inflammation toward
fibrosis is Smad3 dependent, because it developed only
in WT control mice and not in Smad3-null mice (Bonniaud
et al., 2005). Taken together, present results support the
view that Smad3 regulates IL-6 and IL-1b expression in
allergen-induced skin inflammation. Reduced production of
these proinflammatory cytokines in the skin may in turn
cause diminished skin fibrosis leading to reduced dermal
thickening.
Mast cells play an important role in allergic responses
owing to the secretion of a variety of inflammatory mediators
after appropriate activation. Depending on the circum-
stances, the cell could phenotypically express a wide
spectrum of variation in the types, kinetics, and/or magnitude
of its secretory functions (Galli et al., 2005). We found
increased numbers of mast cells in the skin of OVA-sensitized
Smad3/ mice suggesting that the TGF-b–Smad3 pathway
regulates mast cell fate in the allergen-sensitized skin. Mast
cells, eosinophils, and other cells recruited to the site of
inflammation are potential sources of TGF-b. The role of
TGF-b and factors affecting mast cell migration are largely
unknown. Smads appear to be involved in TGF-b1-mediated
mast cell migration and also TGF-b1-mediated mast cell-
growth inhibition (Olsson et al., 2001). Olsson et al. (2001)
found that TGF-b1 induced migration of the human mast cell
line at 40 fM, whereas growth inhibition of mast cells was
detected at 400 pM. They also demonstrated that signals
induced by TGF-b1 that lead to cell migration diverge from
the signals for growth inhibition in mast cells.
Severity of AD correlates with elevated levels of IgE (Flohr
et al., 2004; Boguniewicz et al., 2006). It is of interest that in
this study, OVA-specific IgE levels, but not OVA-specific
IgG2a levels, were scientifically upregulated in Smad3/
mice compared with their WT controls after EC OVA
sensitization. These results suggest that Smad3 signaling has
an inhibitory effect on the production of allergen-specific IgE
in our model. TGF-b is known to suppress IgE synthesis. Thus,
impaired TGF–-bSmad3 signaling may result in upregulation
of OVA-specific IgE antibodies. In line with this, a
significantly higher proportion of children with AD who
frequently exhibit elevated levels of IgE antibodies demon-
strate a TGF-b1 gene allele, which is associated with lower
production of TGF-b1 cytokine (Arkwright et al., 2001).
In conclusion, the present data indicate that Smad3,
an important mediator of TGF-b signaling, regulates chronic
skin inflammation and systemic IgE antibody production
in a murine model AD. Smad3 deficiency affects the
thickness of dermis, immunological status of the skin through
proinflammatory cytokines, and mast cell infiltration as well
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as specific IgE levels after EC allergen sensitization. The
Smad3 signaling pathway might be a potential target in the
therapy of allergic skin diseases.
MATERIALS AND METHODS
Mice
Smad3 knockout mice have been generated by Deng and co-workers
(Yang et al., 1999) and were bred in our facilities. The resulting
progeny were screened by PCR to identify Smad3/ and WT mice.
Animals between 7 and 10 weeks of age were used and were age-
and sex-matched within each experiment. The mice were housed in
pathogen-free facilities. All animal protocols were approved by the
Finnish Institute of Occupational Health Committee on Animal
Welfare.
Sensitization
Epicutaneous treatment and sensitization of mice was performed as
described previously (Spergel et al., 1998). Briefly, mice were
anesthetized with inhalation of Isofluran (Abbott Laboratories,
Abbott Park, IL). Mouse back skin was shaved with an electric razor
and the shaved area was tape-stripped four times by transparent
adhesive tape (Tegaderm, 3M Health Care, St. Paul, MN) to remove
hair and to introduce a standardized skin injury. A sterile gauze
patch (1 1 cm2) moisturized with 100ml of 0.1% OVA in saline
(OVA group) or 100ml of 0.9% saline (saline group) was put on the
back skin of mice and attached with Tegaderm adhesive tape.
The patches were kept there for 1 week and then removed. Two
weeks later, an identical patch was applied to the same skin site. The
whole experiment contained a total of three 1-week exposures with
a 2-week interval between each exposure. The mice were killed after
the last sensitization week. Blood and skin biopsies were collected
for further analysis. The experiment was performed three times.
Sample collection and skin preparations
The mice were killed after the last sensitization week. Blood was
collected and used for antibody analysis. Skin biopsies from treated
skin areas were used for RNA isolation, histology, and immunohisto-
chemical examination. For histology, the skin was fixed in 10%
formalin, embedded in paraffin wax, routinely processed, sectioned
5mm thick, and stained with hematoxylin and eosin, periodic acid
schiff stain and Masson-trichrome stain, and examined under light
microscopy. For immunohistochemical staining, the skin was
embedded into OCT compound (Sakura, Finetek Europe B.V., The
Netherlands) and quick frozen. The skin samples were cut into 5-mm
sections and stained immunohistochemically with mAbs against
CD11c, CD3, CD4, and CD8 (BD, Pharmingen, San Jose, CA) using
the ChemMate (DakoCytomation, Glostrup, Denmark) staining kit.
ELISA
OVA-specific IgE, IgG1, and IgG2a serum levels were measured by
ELISA method. Ninety-six-well microtiter plates (Nunc, Rochester,
NY) were coated with 100 mg/ml OVA in 0.05 M NaHCO3 (pH 9.6) at
41C overnight. The plates were washed with phosphate-buffered
saline–Tween-20 (0.05%) and blocked with 3% BSA in phosphate-
buffered saline for 2 hours at 201C and washed again. One hundred
microliters of diluted sera (1/10, 1/20, 1/40, 1/80) in 1% BSA–pho-
sphate-buffered saline was incubated at 41C overnight. After
washing, 2 mg of biotin-conjugated rat anti-mouse IgE mAb in 1 ml
of 1% BSA–phosphate-buffered saline was incubated for 2 hours at
201C and washed again. Streptavidin–horseradish peroxidase (BD,
Pharmingen) 1/4000 in 1% BSA was added and incubated for
30 minutes at 201C and washed. Peroxidase substrate (Kirkegaard &
Perry Laboratories, Gaithersburg, MD) was added and absorbance
read at 405 nm with an ELISA reader (Multiskan MS, Labsystems,
Vantaa, Finland). OVA-specific IgG2a was measured by using the
same method described. The plates were coated with 2 mg/ml OVA
in 0.05 M NaHCO3 (pH 9.6). Serial dilutions of sera for IgG2a (1/60,
1/180, 1/540, 1/1620) were used. Bound IgG2a was detected with
biotin-conjugated rat anti-mouse IgG2a mAb (BD, Pharmingen).
RT-PCR
Total RNA from skin was extracted and transcribed into cDNA. Real-
time quantitative PCR was performed with an AbiPrism 7,700
Sequence Detector System (Applied Biosystems, Foster City, CA).
PCR primers and probes were TNF-a, IL-6, IL-1b, IL-4, and IFN-g
(Applied Biosystems), and endogeneous 18S rRNA was used as the
housekeeping gene. The target gene expression was expressed as
relative quantitatives.
Data analysis
Data were analyzed with the GraphPadPrism software. Data are
expressed as meanþ /SEM. Statistical significance was accepted
when Po0.05 using the Mann–Whitney U test.
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